- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05614115
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients on dialysis have a very high risk of heart failure and heart-related death compared to people who do not require dialysis. While treatment options for heart failure have improved over the years for those without kidney disease, there has been very limited discoveries to improve survival for dialysis patients.
Empagliflozin, a new diabetic medication that works by making the kidney put out more sugar in the urine, has recently shown to have significant efficacy to protect the kidney and to reduce heart failure hospitalization and cardiovascular death in both diabetic and non-diabetic patients. Studies suggest that this medication may have benefits on the heart, fat cells, blood vessels, and possibly other organ systems. The benefit remains consistent whether you have diabetes or not. Empagliflozin is now approved by the U.S. Food and Drug Administration (FDA) to treat not only diabetes but also chronic kidney disease and to reduce the risk of cardiovascular death and hospitalization for heart failure in adults regardless of the diabetes status.
The clinical studies, however, have excluded those with severe kidney disease and those requiring dialysis. The safety of empagliflozin in the dialysis patients has not been established, and thus it is not available for people with end-stage kidney disease. If empagliflozin is safe in dialysis patients, it may potentially become a very powerful tool to lower the risk of heart-related complications and prolong survival.
Although empagliflozin is approved by the FDA to treat patients with chronic kidney disease, heart failure, and/or diabetes, our study will evaluate empagliflozin as an investigational drug to assess if it is safe in patients receiving chronic dialysis. If we can establish safety, the next step would be to conduct a larger clinical study to evaluate its ability to lower heart failure and death risk in dialysis patients.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Monique E Cho, MD
- Phone Number: 801-581-8090
- Email: monique.cho@hsc.utah.edu
Study Contact Backup
- Name: Jonathan Gutierrez
- Phone Number: 801-587-1911
- Email: jonathan.gutierrez@utah.edu
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- Recruiting
- University of Utah
-
Contact:
- Jonathan Gutierrez
- Phone Number: 801-587-1911
- Email: jonathan.gutierrez@utah.edu
-
Contact:
- Mary Jane Tinnes
- Phone Number: 801-585-2254
- Email: maryjane.tinnes@hsc.utah.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- include diabetic and non-diabetic adults
- dialysis treatment history of ≥3 months
Exclusion Criteria:
- type 1 diabetes
- ongoing intravenous antibiotic therapy for infectious disease
- active treatment for malignancy
- unhealed lower extremity skin ulceration
- history of Fournier's gangrene
- diabetic ketoacidosis
- severe hypoglycemia (requiring external assistance within the past one year)
- allergy to empagliflozin
- pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Empagliflozin 10mg
Empagliflozin10mg oral: Those randomized to 10 mg daily dose will be treated with 10 mg QD throughout the dose escalation and the treatment phase for a total of 12 weeks.
|
is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.
Other Names:
|
Experimental: Empagliflozin 25mg
Empagliflozin 25 mg oral: Those randomized to 25 mg daily dose will be treated with 10 mg QD for the first 2 weeks before escalating the dose to 25 mg QD in week 3, based on tolerability.
At the end of the dose-escalation phase (weeks 3-4), participants will continue the randomized assignment for additional 8 weeks (weeks 5-12, treatment phase), for a total of 12 weeks.
|
is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.
Other Names:
|
Placebo Comparator: Placebo
Encapsulated placebo with an identical appearance to empagliflozin: Those randomized to placebo will be treated with an oral placebo QD throughout the dose escalation and the treatment phase for a total of 12 weeks.
|
Placebo comparator
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of participants in each intervention group who remain in follow-up and adhere to the full randomized dose of empagliflozin at the end of the 12-week intervention period.
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportions of participants in each group who reduce and/or discontinue treatment for safety
Time Frame: 12-weeks
|
Safety outcomes (to be assessed in each treatment group):
|
12-weeks
|
Proportions of participants in each group who reduce and/or discontinue treatment because of intolerance (i.e., allergy, nausea) or other reasons unrelated to safety (i.e., pill burden, study withdrawal due to transplant)
Time Frame: 12-weeks
|
12-weeks
|
|
Proportions of participants in each group who have ≥ 80% pill count compliance.
Time Frame: 12-weeks
|
12-weeks
|
|
Dialytic clearance of empagliflozin
Time Frame: 4 hours post-dose during hemodialysis
|
4 hours post-dose during hemodialysis
|
|
Long-term accumulation of empagliflozin
Time Frame: 10 weeks
|
10 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB_00155825
- 1R01DK131265 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemodialysis
-
National Taiwan University HospitalCompletedHemodialysis Complication | Hemodialysis-Induced SymptomTaiwan
-
Ain Shams UniversityCompleted
-
Imperial College Healthcare NHS TrustCompletedHemodialysisUnited Kingdom
-
Lawson Health Research InstituteUnknown
-
Tufts Medical CenterWithdrawn
-
Federico II UniversityUnknown
-
Hospital Clinic of BarcelonaSocietat Catalana de NefrologiaCompleted
-
Osaka UniversityCompleted
-
Chinese PLA General HospitalWithdrawn
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States